AR033384A1 - Un polinucleotido sustancialmente purificado que codifica para receptores del factor de diferenciacion de l crecimiento, una celula huesped recombinante, un receptor del factor de diferenciacion del crecimiento, un anticuerpo, una representacion virtual de un receptor gdf, un metodo para modular un - Google Patents
Un polinucleotido sustancialmente purificado que codifica para receptores del factor de diferenciacion de l crecimiento, una celula huesped recombinante, un receptor del factor de diferenciacion del crecimiento, un anticuerpo, una representacion virtual de un receptor gdf, un metodo para modular unInfo
- Publication number
- AR033384A1 AR033384A1 ARP010103595A ARP010103595A AR033384A1 AR 033384 A1 AR033384 A1 AR 033384A1 AR P010103595 A ARP010103595 A AR P010103595A AR P010103595 A ARP010103595 A AR P010103595A AR 033384 A1 AR033384 A1 AR 033384A1
- Authority
- AR
- Argentina
- Prior art keywords
- differentiation factor
- growth differentiation
- cell
- substantially purified
- myostatin
- Prior art date
Links
- 230000004069 differentiation Effects 0.000 title abstract 3
- 102000004472 Myostatin Human genes 0.000 abstract 6
- 108010056852 Myostatin Proteins 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 4
- 210000000577 adipose tissue Anatomy 0.000 abstract 3
- 230000026683 transduction Effects 0.000 abstract 3
- 238000010361 transduction Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Animal Husbandry (AREA)
- Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Abstract
Se suministra un polinucleotido que codifica un receptor del factor de diferenciacion del crecimiento (GDF) sustancialmente purificado, que incluye un receptor de GDF-8 (miostatina), como también sus porciones de péptido funcional. Además, se suministra una representacion virtual de un receptor de GDF o su porcion de péptido funcional. Se provee, además, un método para modular el efecto de la miostatina en una célula mediante el contacto de la célula con un agente que afecta la transduccion de la senal de miostatina en la célula. Además, se provee el uso de dicho polinucleotido para la manufactura de un medicamento para aliviar la severidad de una condicion patologica, implicada, por lo menos en parte, por una cantidad anormal, el desarrollo o la actividad metabolica, de un tejido muscular o adiposo en un sujeto, por medio de la modulacion de la transduccion de la senal miostatina en una célula muscular o una célula de tejido adiposo en el sujeto. Se suministra, además, un método para modular el crecimiento del tejido muscular o tejido adiposo en un organismo eucariotico mediante la administracion de un agente que afecta la transduccion de la senal de miostatina en el organismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/626,896 US6656475B1 (en) | 1997-08-01 | 2000-07-27 | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
AR033384A1 true AR033384A1 (es) | 2003-12-17 |
Family
ID=24512319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010103595A AR033384A1 (es) | 2000-07-27 | 2001-07-27 | Un polinucleotido sustancialmente purificado que codifica para receptores del factor de diferenciacion de l crecimiento, una celula huesped recombinante, un receptor del factor de diferenciacion del crecimiento, un anticuerpo, una representacion virtual de un receptor gdf, un metodo para modular un |
Country Status (19)
Country | Link |
---|---|
US (1) | US6656475B1 (es) |
EP (2) | EP2322199B1 (es) |
JP (2) | JP5153985B2 (es) |
CN (2) | CN101402955A (es) |
AR (1) | AR033384A1 (es) |
AT (1) | ATE503487T1 (es) |
AU (2) | AU8299901A (es) |
BR (1) | BR0112788A (es) |
CA (1) | CA2417568C (es) |
DE (1) | DE60144334D1 (es) |
DK (1) | DK1317485T3 (es) |
ES (2) | ES2532406T3 (es) |
IL (2) | IL153975A0 (es) |
MX (1) | MXPA03000787A (es) |
NZ (2) | NZ535074A (es) |
PL (1) | PL365792A1 (es) |
PT (1) | PT1317485E (es) |
WO (1) | WO2002010214A2 (es) |
ZA (1) | ZA200300480B (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
ES2201076T3 (es) * | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
KR20040094709A (ko) * | 2002-02-21 | 2004-11-10 | 와이어쓰 | 폴리스타틴 도메인을 포함하는 단백질 |
PL374966A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
AU2003267246A1 (en) * | 2002-09-16 | 2004-04-30 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
CN1829532A (zh) * | 2003-06-02 | 2006-09-06 | 惠氏公司 | 肌肉抑制素(gdf8)抑制剂和皮质类固醇联合用于治疗神经肌肉紊乱的用途 |
SG153874A1 (en) * | 2003-12-31 | 2009-07-29 | Schering Plough Ltd | Neutralizing epitope-based growth enhancing vaccine |
JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
KR20070026650A (ko) | 2004-05-27 | 2007-03-08 | 악셀레론 파마 인코포레이티드 | 케르베루스/코코 유도체 및 그의 용도 |
US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
CA2574777C (en) | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
JP2008506787A (ja) * | 2004-07-29 | 2008-03-06 | シェーリング−プラウ・リミテッド | 動物においてミオスタチン活性を調節または阻害して赤身組織の成長増加を導くalk5インヒビターの使用 |
CA2575563A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
ATE552272T1 (de) * | 2004-09-30 | 2012-04-15 | Orico Ltd | Myostatin-isoform |
JP2008000003A (ja) * | 2004-10-01 | 2008-01-10 | Oncorex Inc | Pim−1活性/蛋白阻害医薬品 |
US7432079B2 (en) * | 2004-12-30 | 2008-10-07 | Schering-Plough Animal Health Corporation | Plant virus coat fusion proteins with GDF8 epitopes and vaccines thereof |
CN101137906A (zh) * | 2005-03-23 | 2008-03-05 | 惠氏公司 | 对gdf-8调节剂的免疫应答的检测 |
CN100393320C (zh) * | 2005-06-24 | 2008-06-11 | 奥林格斯技术有限公司 | 治疗肌肉萎缩的寡核苷酸药物 |
GB2441581B (en) * | 2005-06-24 | 2011-01-19 | Roderic M K Dale | Compositions and methods for the treatment of muscle wasting |
KR101135220B1 (ko) * | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
EP1973559B1 (en) | 2005-11-23 | 2013-01-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CA2856436A1 (en) * | 2005-12-06 | 2007-06-14 | Amgen Inc. | Uses of myostatin antagonists |
JP2007306885A (ja) * | 2006-05-22 | 2007-11-29 | Mitsubishi Chemicals Corp | 新規非ヒト動物 |
US8097596B2 (en) * | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
AU2006345724B2 (en) * | 2006-06-30 | 2013-11-21 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
WO2008005019A1 (en) * | 2006-07-07 | 2008-01-10 | Dale Roderic M K | Compositions and methods for the treatment of muscle wasting |
JP2009545313A (ja) | 2006-08-03 | 2009-12-24 | オリコ・リミテッド | ミオスタチンアンタゴニスト |
WO2008030706A2 (en) * | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anti-myostatin antibodies |
AU2007332819A1 (en) | 2006-12-08 | 2008-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
RS52537B (en) * | 2006-12-18 | 2013-04-30 | Acceleron Pharma Inc. | ACTIVIN-ACTRII ANTAGONISTS AND USES FOR ANEMIA TREATMENT |
US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
TWI480048B (zh) * | 2007-02-01 | 2015-04-11 | Acceleron Pharma Inc | 活化素-ActRIIa拮抗劑及其治療或預防乳癌之用途 |
TW201627320A (zh) * | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TW201808334A (zh) * | 2007-02-09 | 2018-03-16 | 艾瑟勒朗法瑪公司 | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
EP2207562B1 (en) | 2007-09-18 | 2017-05-31 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
CA2729100C (en) | 2008-06-26 | 2018-01-02 | Acceleron Pharma Inc. | Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
TW201803586A (zh) * | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
BRPI0920962A2 (pt) | 2008-11-26 | 2016-07-12 | Amgen Inc | variantes de polipeptídeos receptores de activina iib e usos dos mesmos |
US8138142B2 (en) * | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
CA2993053A1 (en) * | 2009-04-27 | 2010-11-04 | Novartis Ag | Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth |
EP3345921A1 (en) | 2009-06-08 | 2018-07-11 | Acceleron Pharma Inc. | Use of anti-actriib antibodies for increasing thermogenic adipocytes |
ES2836534T3 (es) | 2009-06-12 | 2021-06-25 | Acceleron Pharma Inc | Proteínas de fusión de ActRIIB-Fc truncadas |
CA2779472C (en) * | 2009-11-03 | 2021-03-16 | Acceleron Pharma Inc. | The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
EA201491231A8 (ru) | 2011-12-19 | 2015-01-30 | Амген Инк. | Варианты полипептидов рецептора активина и их применение |
CN104487574B (zh) | 2012-04-18 | 2017-07-07 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
CN104936605A (zh) | 2012-11-02 | 2015-09-23 | 细胞基因公司 | 激活素-actrii拮抗剂和用于治疗骨和其它病症的用途 |
CA3023553A1 (en) * | 2012-11-06 | 2014-05-15 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
AU2014212014A1 (en) | 2013-02-01 | 2015-08-27 | Amgen Inc. | Administration of an anti-activin-A compound to a subject |
EP4140497A1 (en) | 2013-04-08 | 2023-03-01 | President and Fellows of Harvard College | Compositions for rejuvenating skeletal muscle stem cells |
EP3816625A1 (en) * | 2013-05-06 | 2021-05-05 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
US20160220640A1 (en) | 2013-06-11 | 2016-08-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for increasing neurogenesis and angiogenesis |
WO2015070076A2 (en) * | 2013-11-08 | 2015-05-14 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating neuromuscular junctions |
US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
BR112016028520A2 (pt) | 2014-06-04 | 2017-10-24 | Acceleron Pharma Inc | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina |
WO2015192111A1 (en) | 2014-06-13 | 2015-12-17 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
KR102556991B1 (ko) | 2014-12-03 | 2023-07-19 | 셀진 코포레이션 | 액티빈-ActRII 길항제 및 빈혈 치료를 위한 용도 |
JP2018510637A (ja) | 2015-03-26 | 2018-04-19 | アクセルロン ファーマ, インコーポレイテッド | フォリスタチン関連融合タンパク質およびその使用 |
ES2856001T3 (es) | 2015-04-22 | 2021-09-27 | Biogen Ma Inc | Nuevas proteínas híbridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular |
IL305148A (en) | 2015-09-15 | 2023-10-01 | Scholar Rock Inc | Anti-pro/hidden myostatin antibodies and their uses |
JP6948331B2 (ja) | 2016-01-06 | 2021-10-13 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する |
JP2019504064A (ja) | 2016-01-08 | 2019-02-14 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | 抗プロ/潜在型ミオスタチン抗体およびその使用方法 |
KR102457751B1 (ko) | 2016-03-10 | 2022-10-21 | 악셀레론 파마 인코포레이티드 | 액티빈 타입 2 수용체 결합 단백질 및 이의 용도 |
CN105699661A (zh) * | 2016-03-14 | 2016-06-22 | 陈倩 | Smad6在肝癌诊断治疗中的应用 |
HUE051480T2 (hu) | 2016-06-13 | 2021-03-01 | Scholar Rock Inc | Miosztatin-inhibitorok alkalmazása és kombinációs terápiák |
AU2018205270B2 (en) | 2017-01-06 | 2022-08-11 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
CN107267637B (zh) * | 2017-07-25 | 2021-08-24 | 华南农业大学 | 一种鸡肌间脂肪宽度相关的分子标记及其应用 |
CN109540818A (zh) * | 2018-12-21 | 2019-03-29 | 云南农业大学 | 一种基于钙、磷血液生化标记选育武定鸡的方法 |
CN109754858B (zh) * | 2019-01-11 | 2021-09-21 | 余鹏 | 甲氨蝶呤给药方案确定装置、存储介质及设备 |
JOP20220057A1 (ar) | 2019-09-03 | 2023-01-30 | Novartis Ag | علاج أمراض أو اضطرابات الكبد تشتمل على مضادات مستقبل actrii |
CN116600824A (zh) | 2020-07-10 | 2023-08-15 | 巴斯德研究所 | Gdf11诊断和治疗焦虑症和抑郁症的用途 |
CN113223607B (zh) * | 2021-05-28 | 2023-10-20 | 北京化工大学 | 采用smiles算法随机批量生成肝素类似物结构坐标的方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5314695A (en) | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
IL132922A0 (en) * | 1997-05-16 | 2001-03-19 | Procter & Gamble | The use of a bone morphogenetic protein (bmp) receptor complex for screening |
AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
AU2586199A (en) * | 1998-02-05 | 1999-08-23 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
EP1132472A4 (en) * | 1998-11-13 | 2004-04-14 | Takeda Chemical Industries Ltd | NEW PROTEIN AND ITS APPLICATION |
MXPA01007366A (es) * | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
WO2001053350A1 (en) * | 2000-01-18 | 2001-07-26 | Agresearch Limited | Myostatin and mimetics thereof |
-
2000
- 2000-07-27 US US09/626,896 patent/US6656475B1/en not_active Expired - Lifetime
-
2001
- 2001-07-26 EP EP10183121.2A patent/EP2322199B1/en not_active Expired - Lifetime
- 2001-07-26 ES ES10183121.2T patent/ES2532406T3/es not_active Expired - Lifetime
- 2001-07-26 BR BR0112788-8A patent/BR0112788A/pt not_active IP Right Cessation
- 2001-07-26 JP JP2002515943A patent/JP5153985B2/ja not_active Expired - Fee Related
- 2001-07-26 AU AU8299901A patent/AU8299901A/xx active Pending
- 2001-07-26 AT AT01961756T patent/ATE503487T1/de active
- 2001-07-26 CA CA2417568A patent/CA2417568C/en not_active Expired - Fee Related
- 2001-07-26 NZ NZ535074A patent/NZ535074A/en not_active IP Right Cessation
- 2001-07-26 DK DK01961756.2T patent/DK1317485T3/da active
- 2001-07-26 EP EP01961756A patent/EP1317485B1/en not_active Expired - Lifetime
- 2001-07-26 ES ES01961756T patent/ES2364126T3/es not_active Expired - Lifetime
- 2001-07-26 MX MXPA03000787A patent/MXPA03000787A/es active IP Right Grant
- 2001-07-26 AU AU2001282999A patent/AU2001282999B2/en not_active Ceased
- 2001-07-26 PT PT01961756T patent/PT1317485E/pt unknown
- 2001-07-26 PL PL01365792A patent/PL365792A1/xx not_active Application Discontinuation
- 2001-07-26 WO PCT/US2001/023615 patent/WO2002010214A2/en active Application Filing
- 2001-07-26 IL IL15397501A patent/IL153975A0/xx unknown
- 2001-07-26 NZ NZ523617A patent/NZ523617A/en not_active IP Right Cessation
- 2001-07-26 CN CNA2008101449332A patent/CN101402955A/zh active Pending
- 2001-07-26 CN CNB018149081A patent/CN100422212C/zh not_active Expired - Lifetime
- 2001-07-26 DE DE60144334T patent/DE60144334D1/de not_active Expired - Lifetime
- 2001-07-27 AR ARP010103595A patent/AR033384A1/es unknown
-
2003
- 2003-01-17 ZA ZA200300480A patent/ZA200300480B/en unknown
-
2009
- 2009-05-18 IL IL198800A patent/IL198800A0/en unknown
-
2012
- 2012-06-29 JP JP2012147832A patent/JP5785525B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2004504832A (ja) | 2004-02-19 |
AU8299901A (en) | 2002-02-13 |
PT1317485E (pt) | 2011-07-06 |
EP2322199B1 (en) | 2014-12-10 |
JP5785525B2 (ja) | 2015-09-30 |
EP1317485A2 (en) | 2003-06-11 |
WO2002010214A3 (en) | 2003-04-03 |
CA2417568A1 (en) | 2002-02-07 |
BR0112788A (pt) | 2003-09-09 |
IL198800A0 (en) | 2010-02-17 |
PL365792A1 (en) | 2005-01-10 |
JP2012235781A (ja) | 2012-12-06 |
WO2002010214A2 (en) | 2002-02-07 |
ZA200300480B (en) | 2004-01-27 |
CN1449410A (zh) | 2003-10-15 |
ES2532406T3 (es) | 2015-03-26 |
ATE503487T1 (de) | 2011-04-15 |
AU2001282999C1 (en) | 2002-02-13 |
AU2001282999B2 (en) | 2006-12-14 |
DE60144334D1 (de) | 2011-05-12 |
CA2417568C (en) | 2014-07-08 |
EP2322199A1 (en) | 2011-05-18 |
CN100422212C (zh) | 2008-10-01 |
US6656475B1 (en) | 2003-12-02 |
NZ523617A (en) | 2005-05-27 |
DK1317485T3 (da) | 2011-07-18 |
NZ535074A (en) | 2005-12-23 |
EP1317485B1 (en) | 2011-03-30 |
JP5153985B2 (ja) | 2013-02-27 |
ES2364126T3 (es) | 2011-08-25 |
CN101402955A (zh) | 2009-04-08 |
IL153975A0 (en) | 2003-07-31 |
MXPA03000787A (es) | 2004-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR033384A1 (es) | Un polinucleotido sustancialmente purificado que codifica para receptores del factor de diferenciacion de l crecimiento, una celula huesped recombinante, un receptor del factor de diferenciacion del crecimiento, un anticuerpo, una representacion virtual de un receptor gdf, un metodo para modular un | |
BR0209191A (pt) | Uso de folistatina para aumentar a massa muscular | |
HUP0102511A2 (hu) | Kombinált gyógykezelés bipoláris betegségek kezelésére | |
TNSN07247A1 (en) | Cosmetic composition for skin application suitable for relaxing expression wrinkles | |
HN1998000155A (es) | Medicamentos | |
PE20000033A1 (es) | Articulo absorbente altamente eficaz para utilizarse con trusa menstrual | |
MX9204881A (es) | Composicion farmaceutica que comprende moleculas activas, receptoras de calcio. | |
AR047712A1 (es) | Metodo de tratamiento de una lesion de tejido esqueletico blando natural administrando una composicion de celulas madre mesenquimatosas | |
ES534488A0 (es) | Procedimiento para preparar una suspension de un derivado de insulina | |
BR0009964A (pt) | Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial | |
AR008444A1 (es) | Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii | |
CO5150232A1 (es) | METODO Y COMBINACION QUE UTILIZAN (+) NORCISAPRIDA EN COMBINACION CON INHIBIDORES DE BOMBA DE PROTONES O ANTAGONISTAS DEL RECEPTOR H[sub 2] | |
DE3778770D1 (de) | Neue diphenylpropylamin-derivate, ihre herstellung sowie ihre pharmazeutische verwendung. | |
NO971341D0 (no) | Promoter for reseptor tyrosinkinase TIE | |
ATE330588T1 (de) | Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen | |
VERBOV | Buschke‐Ollendorff syndrome (disseminated dermatofibrosis with osteopoikilosis) | |
PL360492A1 (en) | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates | |
KR890004690A (ko) | 당뇨병의 치료를 위한 베자피브레이드의 용도 | |
AR020832A1 (es) | Procedimiento para la preparacion de una composicion de alta pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5-(10)-en-20-in-3-ona | |
HK1053852A1 (en) | Use of low ionic strength ophthalmic compositions | |
BR9911237A (pt) | Novo uso de um derivado de piridazinona | |
BR9915214A (pt) | Combinações contendo um beta-agonista e umagente anti-diabético adicional | |
ES2196171T3 (es) | Agentes antitumorales de tioxantenona liofilizada. | |
DE50109796D1 (de) | Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels | |
AR014969A1 (es) | Formulacion que contienen por lo menos una proteina tardia (proteina l) de uno o mas papilomavirus y/o por lo menos una proteina temprana (proteina e) deuno o mas papilomavirus, procedimiento para la preparacion de la formulacion mencionada asi como su utilizacion para la manufactura de un medicamen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |